HIGHLIGHTS
- who: Hikmat Abdel-Razeq and collaborators from the Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan School of Medicine, University of Jordan, Amman, Jordan have published the paper: Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer, in the Journal: (JOURNAL) of 12/07/2022
- what: The study was terminated early, and final analysis showed that patients treated with capecitabine had a better 5-year DFS than the control group (74.1% versus 67.6%; hazard ratio for recurrence, second cancer, or death, 0.70; 95% CI . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.